VCL-ALK renal cell carcinoma in children with sickle-cell trait: The eighth sickle-cell nephropathy?

American Journal of Surgical Pathology

Volumn 38, Issue 6, 2014, Pages 858-863

  Smith, Nathaniel E ^a   Deyrup, Andrea T ^a   Mariño Enriquez, Adrian ^a   Fletcher, Jonathan A ^a   Bridge, Julia A ^b   Illei, Peter B ^a   Netto, George J ^a,c   Argani, Pedram ^a,d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE GREENVILLE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anaplastic lymphoma kinase; Renal cell carcinoma; Vinculin

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE; TUMOR MARKER; VCL PROTEIN, HUMAN; VINCULIN;

ARTICLE; CASE REPORT; CHILD; ENZYMOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; NEPHRECTOMY; PATHOLOGY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SICKLE CELL TRAIT;

CARCINOMA, RENAL CELL; CHILD; GENE FUSION; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; PHENOTYPE; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SICKLE CELL TRAIT; TUMOR MARKERS, BIOLOGICAL; VINCULIN;

EID: 84900847567     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000179     Document Type: Article

References (37)

1. Tsaras G, Owusu-Ansah A, Boateng FO, et al. Complications associated with sickle cell trait: A brief narrative overview. Am J Med. 2009;122:507-512
2. Berman LB. Sickle cell nephropathy. JAMA. 1974;228:1279
3. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19:1-11
4. Assad L, Resetkova E, Oliveira VL, et al. Cytologic features of renal medullary carcinoma. Cancer. 2005;105:28-34
5. Avery RA, Harris JE, Davis CJ Jr, et al. Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor. Cancer. 1996;78:128-132
6. Dimashkieh H, Choe J, Mutema G. Renal medullary carcinoma: A report of 2 cases and review of the literature. Arch Pathol Lab Med. 2003;127:e135-e138
7. Gatalica Z, Lilleberg SL, Monzon FA, et al. Renal medullary carcinomas: Histopathologic phenotype associated with diverse genotypes. Hum Pathol. 2011;42:1979-1988
8. Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: The Bronx experience. Urology. 2007;70:878-882
9. Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int. 2010;106: 62-65
10. Simpson L, He X, Pins M, et al. Renal medullary carcinoma and ABL gene amplification. J Urol. 2005;173:1883-1888
11. Stahlschmidt J, Cullinane C, Roberts P, et al. Renal medullary carcinoma: Prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med Pediatr Oncol. 1999;33:551-557
12. Watanabe IC, Billis A, Guimaraes MS, et al. Renal medullary carcinoma: Report of seven cases from Brazil. Mod Pathol. 2007;20:914-920
13. Wesche WA, Wilimas J, Khare V, et al. Renal medullary carcinoma: A potential sickle cell nephropathy of children and adolescents. Pediatr Pathol Lab Med. 1998;18:97-113
14. Yang XJ, Sugimura J, Tretiakova MS, et al. Gene expression profiling of renal medullary carcinoma: Potential clinical relevance. Cancer. 2004;100:976-985
15. Cheng JX, Tretiakova M, Gong C, et al. Renal medullary carcinoma: Rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol. 2008;21:647-652
16. Hollmann TJ, Hornick JL. INI1-deficient tumors: Diagnostic features and molecular genetics. Am J Surg Pathol. 2011;35:e47-e63
17. Elwood H, Chaux A, Schultz L, et al. Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma. Urology. 2011;78:e1-e5
18. Judkins AR. Immunohistochemistry of INI1 expression: A new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol. 2007;14:335-339
19. Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: New representative of ALK-Associated tumor spectrum. Mod Pathol. 2011;24:430-442
20. Marinño-Enñríquez A, Ou WB, Weldon CB, et al. ALK rearrangement in sickle cell trait-Associated renal medullary carcinoma. Genes Chromosomes Cancer. 2011;50:146-153
21. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer. Cancer. 2012;118:4427-4436
22. Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: Frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol. 2012;25:1516-1525
23. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284
24. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999; 59:2776-2780
25. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157:377-384
26. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566
27. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131:1190-1203
28. Johnson RP, Craig SW. F-Actin binding site masked by the intramolecular association of vinculin head and tail domains. Nature. 1995;373:261-264
29. Hemler M. Integrins. Guidebook to the Extracellular Matrix, Anchor, and Adhesion Proteins. 2nd ed. Oxford: Oxford University Press; 1999:196-216
30. Srigley JR, Delahunt B, Eble JN, et al. and the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37:1469-1489
31. Weeks DA, Beckwith JB, Mierau GW. Benign nodal lesions mimicking metastases from pediatric renal neoplasms: A report of the National Wilms' Tumor Study pathology center. Hum Pathol. 1990;21:1239-1244
32. Mano H. ALKoma: A cancer subtype with a shared target. Cancer Discov. 2012;2:495-502
33. Gunby RH, Sala E, Tartari CJ, et al. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem. 2007;7:594-611
34. Hodge JC, Pearce KE, Sukov WR. Distinct ALK-rearranged and VCL-negative papillary renal cell carcinoma variant in two adults without sickle cell trait. Mod Pathol. 2013;26:604-605
35. Debelenko LV. Reply to "Distinct ALK-rearranged and VCLnegative papillary renal cell carcinoma variants in two adults without sickle cell trait'. Mod Pathol. 2013;26:605-607
36. Albadine R, Wang W, Brownlee NA, et al. Topoisomerase II alpha status in renal medullary carcinoma: Immuno-expression and gene copy alterations of a potential target of therapy. J Urol. 2009;182: 735-740
37. Kwak EL, Bang Y, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693-1703.